Journal profile · ONCOLOGY
Translational Breast Cancer Research
ISSN 2218-6778 · AME Publishing Company
Translational Breast Cancer Research: CAS Zone 4 · Medicine (2026 Xinrui edition); impact factor 3.9 (journal website); hybrid open access; median 108 days to acceptance (86 articles, last 24 months); 39 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Translational Breast Cancer Research is published by AME Publishing Company and is classed under Medicine in the CAS Journal Ranking. By OpenAlex counts of its recent articles, its largest topics are Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies and HER2/EGFR in Cancer Research, together about 49.3% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Translational Breast Cancer Research (Transl Breast Cancer Res, TBCR, Online ISSN 2218-6778) launched in November 2019, is an open access, peer-reviewed journal focusing on translational research in breast cancer.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology18.2%
- Advanced Breast Cancer TherapiesMedicine17.2%
- HER2/EGFR in Cancer ResearchMedicine14%
- Breast Lesions and CarcinomasMedicine6.4%
- Cancer Treatment and PharmacologyMedicine5.7%
- Cancer Immunotherapy and BiomarkersMedicine3.2%
- Cancer Cells and MetastasisMedicine2.8%
- Breast Implant and ReconstructionMedicine2.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePMCPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 3.9Publisher website ·
- CiteScore 2026-06
- 3.4LetPub ·
- CiteScore (publisher) 2025
- 3.4Publisher website ·
- SJR 2026-06
- 0.89LetPub ·
- SNIP 2026-06
- 0.86LetPub ·
- h-index
- 14OpenAlex ·
- i10-index
- 28OpenAlex ·
- 2-year mean citedness
- 3.92OpenAlex ·
- Self-citation rate
- 2.6%LetPub ·
- Share of gold OA articles
- 79.07%LetPub ·
Volume
- Articles per year
- 31LetPub ·
- Articles per year (publisher)
- 2,022Publisher website ·
Articles by year OpenAlex count · 261 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 41 | 41 | 13 |
| 2025 | 39 | 39 | 121 |
| 2024 | 38 | 38 | 329 |
| 2023 | 36 | 36 | 192 |
| 2022 | 37 | 37 | 206 |
| 2021 | 39 | 39 | 103 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
108 daysMedian, submission to acceptance · P25–P75 77 days – 139 days
- Acceptance to online
- median 56 days (86 articles)
- Submission to online
- median 162 days
- Sample
- 86 articles with submission and acceptance dates (91 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteLicense & copyright, Open access
- License & copyright Copyright
For open access publishing, this journal uses an exclusive licensing agreement. Authors will transfer copyright to AME Publishing Company, but will have the right to share their article in the same way permitted to third parties under the relevant user license, as well as certain scholarly usage rights.
Source ↗Publisher website ·- Open access Open Access Statement
Translational Breast Cancer Research is a peer reviewed, open access journal. All content of the journal is published under the Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). All articles published open access will be immediately and permanently free for all to read, download, copy and distribute as defined by the applied license.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- AME Publishing Company
- ISSN
- 2218-6778
- Official links
- Journal homepage ↗OpenAlex
FAQ
Frequently asked questions about Translational Breast Cancer Research
What CAS zone is Translational Breast Cancer Research in?
In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Translational Breast Cancer Research?
The journal's website gives an impact factor of 3.9; this is the journal's own figure, as LetPub lists none for it; CiteScore 3.4, h-index 14.
How long does peer review take at Translational Breast Cancer Research?
Based on the dates recorded on 86 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 108 days (interquartile range 77–139 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Translational Breast Cancer Research?
According to LetPub and DOAJ records, Translational Breast Cancer Research is indexed in ESCI and Scopus. The journal's website also lists Web of Science and PMC; that list has not been checked against each database.
Is Translational Breast Cancer Research open access, and what is the APC?
Translational Breast Cancer Research is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .